FGFR family inhibitors (pazopanib, regorafenib, ponatinib). Overexpression may be a mechanism of acquired resistance to gefitinib. FGFR1 amplification may contribute to resistance to hormonal therapy in ER+ breast cancers. Here, FGFR1 is linked to breast cancer.